Answers are grounded in this paper and cite their sources.
Background: Systemic sclerosis (SSc) is a rare chronic inflammatory disorder characterized by diffuse fibrosis and vascular abnormalities in the skin and internal organs. Interleukin-23 (IL-23) is a pro-inflammatory cytokine that can enhance the expansion of T helper 17 (Th17) cells and thus plays a critical role in many inflammatory autoimmune diseases. This study aimed to assess the salivary IL-23 levels in Iranian patients with SSc compared to healthy individuals. Methods: In this cross-sectional study, unstimulated saliva samples (5 cc) were collected from 88 SSc patients and 88 age- and sex-matched healthy individuals. The salivary levels of IL-23 in the saliva samples were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Results: The mean salivary levels of IL-23 in the patient group were significantly higher than in the control subjects (164.5±22.1 ng/L vs. 95.8±15.7 ng/L, P<0.0001). In SSc patients, the salivary IL-23 levels were significantly elevated in ACA-positive compared to ACA-negative participants (179.8±11.2 ng/L vs. 144.3±15.7 ng/L, P<0.0001). However, IL-23 was not associated with gender or age (P>0.05). Conclusion: The results suggest that IL-23 is associated with the pathogenesis of SSc; therefore, this pro-inflammatory cytokine is not only a valuable supportive biomarker for monitoring the disease progression but also blocking IL-23 could be considered a potential therapeutic target, especially in early SSc. Further comprehensive studies are needed to confirm our findings.
No takes yet. Share an insight, caveat, or question.
Tadayon et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: